Introduction
Interleukin-4 (IL-4) is best known for its role in allergic disease, exerting its effects largely through the induction of Th2 differentiation and IgE production. 1 Allergic disease pathology is marked by the recruitment of inflammatory cells, including macrophages. Recent reports have emphasized the distinct roles that Th1 and Th2 cytokines play in directing macrophage activation, which can greatly alter disease outcome. In this realm, it is now appreciated that unlike the patent inhibitory functions of IL-10, IL-4 can direct a program of 'alternative' macrophage activation. [2] [3] [4] This process includes the selective upregulation of major histocompatibility complex (MHC) class II molecules and the mannose receptor. Coupled with decreased synthesis of tumor necrosis factor-a (TNF-a) and upregulation of the IL-1 decoy receptor (IL-1R type-II), these IL-4 activities collectively dampen macrophage inflammatory functions while increasing antigen presentation. Hence, a more complete understanding of IL-4 signaling in macrophages may provide insight into both inflammatory disease processes and normal immune function.
Cytokine signaling is conveyed in part through receptor-mediated activation of Janus family tyrosine kinases (JAKs) and signal transducers and activators of transcription (STATs). The 'classical' macrophage activation pathway is activated by the Th1-type cytokine, IFN-g. IFN-g induces rapid activation of the transcription factor, STAT1, and induction of STAT1-responsive genes such as inducible nitric oxide synthetase (iNOS) and IP-10 (CXCL10). In contrast, the 'alternative' macrophage activation pathway is activated by the Th2-type cytokine, IL-4. IL-4 activates STAT6 and expression of STAT6-responsive genes such as arginase-I and 15-lipoxygenase. In many cases, STAT gene deletion completely blocks cytokine signal transduction, demonstrating the critical nature of this pathway. For example, loss of STAT6 expression results in defective Th2 development and IgE synthesis. 5, 6 Given that macrophages mediate many inflammatory processes and that activation of macrophages is strongly regulated by cytokines, it is clear that cytokine signaling must be tightly controlled to avoid immunopathology.
Cytokine receptor signal transduction, in particular STAT activation, is controlled in part via the induction of the feedback regulatory proteins, suppressors of cytokine signaling (SOCS). 7 There are eight SOCS gene family members (SOCS-1 to SOCS-7 and CIS). We have previously shown that both type-I (IFN-a/b) and type-II (IFN-g) interferons induce SOCS-1 expression, and that SOCS-1 overexpression can block activation of STAT6 in macrophages. 8 In addition, several related studies by others showed that forced expression of SOCS-1 in various tumor cell lines inhibits IL-4 signaling. 9, 10 However, none of these studies examined whether SOCS-1 serves as an endogenous regulator of IL-4 signaling. Given the importance of IL-4 in directing 'alternative' macrophage activation, we investigated the ability of IL-4 itself to induce SOCS gene expression in primary macrophages, and defined the importance of this pathway by examining IL-4 signaling in SOCS-1 deficient macrophages. Our studies reveal a selective pattern of SOCS gene expression in macrophages that is critical for regulating IL-4-mediated STAT6 activation and the induction of STAT6-responsive genes.
Results

IL-4 induces SOCS-1 gene expression in monocytes and macrophages
We have previously shown that type-I and -II interferons induce SOCS-1 expression in monocytes. 8 To determine if IL-4 itself can induce expression of SOCS-1 in monocytes, we treated normal human monocytes with IL-4 (10 ng/ ml) for various time periods, and measured SOCS-1 gene expression by Northern blotting. As shown in Figure 1a , IL-4 induced rapid expression of SOCS-1 mRNA that peaked at approximately 90 min post-treatment. The induction of SOCS-1 gene expression by IL-4 was rapid but relatively short-lived, as its mRNA level began to decline by 2 h post-treatment.
Given that SOCS-1 expression can also be induced by both type-I and -II interferons in monocytes, we determined if SOCS-1 expression is broadly inducible by other cytokines that are known to alter macrophage function. Monocytes were treated with IFN-b, IFN-g, IL-4, IL-10, IL-13 or granulocyte-macrophage colony-stimulating factor (GM-CSF) for 2 h, after which SOCS-1 gene expression was measured by RNase protection assay (RPA). As shown in Figure 1b , several of these cytokines, including the IL-4-related cytokine IL-13, induced SOCS-1 gene expression in monocytes. By contrast, neither IL-10 nor GM-CSF induced SOCS-1 expression in monocytes. Thus, induction of the SOCS-1 gene by cytokines showed some selectivity, and was not globally inducible by all cytokines that are known to be active on monocytes. This experiment, as well as all those that follow, were repeated at least three times with similar results.
Induction of the SOCS genes by IL-4 is STAT6-dependent
To determine if IL-4 induces a SOCS gene expression profile in macrophages that is distinct from that induced by IFN-g, we treated primary, murine, bone marrowderived macrophages with IL-4 for 2 h, and then examined expression of the SOCS-1, SOCS-2 and SOCS-3 genes by Northern blotting. Macrophages were also treated with IFN-g or IL-10 for comparison. As shown in Figure 2 , IL-4 induced expression of SOCS-1 and SOCS-2, without inducing expression of SOCS-3. In contrast, IFN-g induced expression of SOCS-1 and SOCS-3 but not SOCS-2. IL-10 induced expression of SOCS-3, but not SOCS-1 or SOCS-2.
Activation of STAT6 is known to be critical for induction of IL-4-mediated gene expression. 5, 6 To determine if the induction of SOCS-1 and SOCS-2 gene Figure 2 , induction of SOCS gene expression by IL-4 was completely ablated in the absence of STAT6. By contrast, the absence of STAT6 did not prevent the ability of IFN-g to induce expression of SOCS-1 or SOCS-3. Likewise, the ability of IL-10 to induce SOCS-3 gene expression did not require STAT6. These findings demonstrate a differential induction of the SOCS genes by cytokines that exert distinct effects on macrophage activation. These findings also demonstrate the essential requirement for STAT6 in the induction of SOCS gene expression by IL-4, but not by IFN-g or IL-10.
Induction of SOCS gene expression by cytokines is a dynamic process, and the relative levels of SOCS gene expression vary with time following initial exposure to a particular cytokine. To illustrate these changes, we evaluated the levels of SOCS gene expression at various time points following addition of IFN-g, IL-10, IL-4 or GM-CSF to cultures of normal macrophages. As shown in Figure 3 , these cytokines induced differential expression of the SOCS genes in macrophages. IFN-g induced expression of SOCS-1 and SOCS-3; IL-10 induced expression of SOCS-3 alone; IL-4 induced expression of SOCS-1 and SOCS-2 and GM-CSF induced expression of SOCS-2 and SOCS-3. Temporally, the induction of the SOCS-3 gene preceded induction of SOCS-1, and expression of the SOCS-2 gene by IL-4 or GM-CSF was delayed compared to induction of the SOCS-1 and SOCS-3 genes.
In contrast to IL-4, IFN signaling is largely dependent upon STAT1 activation. 11, 12 To determine if IFN-mediated SOCS-1 and SOCS-3 induction in macrophages is STAT1-dependent, we compared the induction of SOCS-1 and SOCS-3 gene expression by bone marrow-derived macrophages from control (STAT1 þ / þ ) and STAT1-deficient (STAT1 indicating that SOCS-3 gene expression may be negatively regulated by SOCS-1. Thus, the induction of SOCS-1 by interferons is STAT1-dependent, whereas the induction of SOCS-1 by IL-4 is STAT6-dependent.
Forced expression of SOCS-1 inhibits IL-4 signaling
Forced expression of SOCS-1 has been shown to block STAT6 DNA-binding activity in fibroblasts and a leukemic B-cell line through its interaction with JAK1. 9, 10 We examined whether ectopic expression of epitope-tagged SOCS-1, SOCS-2 or SOCS-3 inhibits STAT6 DNA-binding and tyrosine phosphorylation in a panel of stably transfected HeLa cell lines. 13 As shown in Figure 5a , IL-4 induced STAT6 tyrosine phosphorylation and DNA-binding activity in the parental cells. However, this activation was completely prevented in cells that constitutively express SOCS-1. Activation of STAT6 by IL-4 was also greatly diminished in the SOCS-3 transfectants. However, forced expression of SOCS-2 did not decrease IL-4-induced STAT6 activation. We confirmed that the SOCS proteins were expressed in these transfectants by Western blotting with an anti-Flag antibody ( Figure 5a , bottom panel).
To confirm that the IL-4-inducible DNA-binding activity that we detected by electrophoretic mobilityshift assay (EMSA) (top panel) is STAT6, we evaluated the ability of several antibodies to 'supershift' the DNAprotein complexes shown in the top panel of Figure 5a . As shown in Figure 5b , the IL-4-inducible DNA-binding activity could be supershifted with an anti-STAT6 antibody, but not with antibodies specific for STAT1 or an unrelated transcription factor, C/EBPb. Our findings indicate that although IL-4 induces expression of both SOCS-1 and SOCS-2 in macrophages, only SOCS-1 serves as a feedback inhibitor of IL-4 signaling. Although IL-4 did not induce expression of SOCS-3 in macrophages, the ability of cytokines such as IFN-g and IL-10 to induce expression of SOCS-3 might explain, at least in part, their ability to negatively regulate IL-4 signaling in macrophages. 
Discussion
Macrophages are central to the inflammatory cascade, serving to phagocytize and kill both pathogens and host cells. Control of their recruitment and function has a tremendous impact on health and disease, and hence, their functions are widely studied. IL-4 is often grouped together with IL-10 as a macrophage inhibitor due to its suppressive effects on the respiratory burst and TNF-a production. However, recent studies have forced a reconsideration of IL-4 activities in regard to macrophage function. The concept of 'alternative' macrophage activation by IL-4 is supported by the ability of IL-4 to enhance antigen presentation, proliferation, chemokine production and chemokine receptor expression. [2] [3] [4] Thus, dysregulated IL-4 signaling may influence inflammatory responses by altering the expression of specific genes in macrophages rather than broadly inhibiting their activation. For these reasons, it is critical that we fully understand how the alternative macrophage activation pathway is regulated.
The SOCS family of inhibitory proteins has emerged as a central means by which cytokine receptor signaling can be extinguished. 7 Induction of SOCS gene transcription and translation provides both negative feedback and . Cell lysates were prepared, and STAT6 activity was measured by EMSA (top panel) using a DNA probe (IL-1ra SBE1) that exhibits a high affinity for STAT6. 34 The levels of tyrosine-phosphorylated STAT6 (pY-STAT6) were measured by Western blotting after first immunoprecipitating STAT6 protein (middle panel). SOCS protein expression was confirmed by Western blotting with an anti-FLAG antibody (bottom panel). (b) To demonstrate the specificity of the DNA probe (IL-1Ra SBE1) used in the EMSA (Figure 4a , top panel), the nuclear protein extract from IL-4-treated parental cells (lane 2) was preincubated for 5 min with 1 ml of rabbit antisera specific for C/EBPb, STAT6 or STAT1 before adding the radiolabeled IL-1Ra SBE1 probe. The samples were analyzed by EMSA for the presence of supershifted complexes. 
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H Dickensheets et al crossinhibition of other cytokine receptors. This is accomplished by directing the degradation of JAK family tyrosine kinases or by blocking STAT-cytokine receptor interactions. In this regard, SOCS-1 and SOCS-3 have been shown to be especially potent and non-redundant inhibitory proteins. SOCS-1-deficient mice die perinatally of a monocytic infiltration in the heart, lungs and pancreas that can be greatly diminished by the simultaneous deletion of IFN-g. 14,15 SOCS-3-deficient mice die at mid-gestation from erythrocytosis-related sequelae. 16 Thus, SOCS-1 and SOCS-3 have been shown to be potent regulators of cytokine signaling in vivo, with particular emphasis on SOCS-1 in macrophage-mediated inflammatory responses.
A previous study by Losman et al. 9 showed that forced expression of SOCS-1 but not SOCS-2 inhibits IL-4 signaling in a murine B-cell line (M12.4.1). Using a panel of HeLa cell transfectants, we also found that SOCS-1 but not SOCS-2 suppresses IL-4 signaling. Our study is the first to demonstrate that IL-4 induces SOCS-1 expression in primary macrophages. More importantly, we show that the absence of SOCS-1 expression in primary macrophages enhances IL-4 signaling and subsequent gene expression. These findings are consistent with our previous demonstration that forced expression of SOCS-1 in the macrophage cell line, RAW264, inhibits activation of a STAT6-driven promoter. 8 However, the current study extends our earlier work by demonstrating that SOCS-1 is also a critical, STAT6-inducible regulator of IL-4 signaling in primary macrophages. Therefore, we found that SOCS-1 regulates activation of macrophages by both the classical IFN-g-inducible pathway as well as the alternative IL-4-inducible pathway.
As the importance of the alternative macrophage activation pathway continues to be revealed, SOCS-1 may be found to be a central player. It is particularly striking that the differential regulation of SOCS family genes includes the common activation of SOCS-1 by IL-4 and IFN-g, two cytokines with opposing effects on the immune response. In contrast, the potent anti-inflammatory cytokine, IL-10, did not induce SOCS-1 expression in macrophages. SOCS-1-deficient mice demonstrated the absolute importance of this gene in regulating IFN-g function.
14,15 Our current study shows that SOCS-1-deficient macrophages also demonstrate negative feedback regulation of IL-4 signaling. Hence, SOCS-1 appears to be a central regulator of macrophage programming that is inducible by signaling through either IL-4 or IFN-g receptors. Induction of SOCS-1 expression by IL-4 or IFN-g can provide both negative feedback and crossreceptor regulation. This theory is consistent with a recent report by Naka et al. 17 showing that administration of IFN-g or IL-4 to SOCS-1 knockout mice accelerates the development of hepatitis, whereas deletion of the STAT1 or STAT6 genes, respectively, decreases this inflammation. Thus, SOCS-1 gene expression can be induced either by STAT1 or by STAT6 activation, and its expression is critical to prevent the deleterious effects of chronic cytokine signaling in macrophages.
In contrast to SOCS-1, we found that SOCS-2 is induced by IL-4 but not by IFN-g or IL-10 in primary macrophages. The function(s) of SOCS-2 in macrophages is unclear because its overexpression did not negatively regulate IL-4 signaling, and it did not inhibit IFN-g signaling. 13 In a related study by others, it was shown that IL-4 induces expression of SOCS-1 but not SOCS-2 in primary human keratinocytes, 18 demonstrating lineagespecific differences in SOCS gene induction that may determine how cytokine networks affect the inflammatory response. Our finding that the induction of SOCS-1 gene expression by IL-4 is STAT6-dependent is consistent with a recent report by Travagli et al. 19 These authors identified an IL-4-responsive element in the promoter of the SOCS-1 gene that contains three distinct STAT6-binding sites. Mutation of these STAT6-binding sites abrogates the ability of IL-4 to trans-activate a reporter gene containing the SOCS-1 promoter.
Although IL-4 and IFN-g share the ability to induce expression of SOCS-1, they do not share the ability to induce expression of SOCS-3 in macrophages. SOCS-3 expression was induced by both the proinflammatory cytokine, IFN-g, and the anti-inflammatory cytokine, IL-10, cytokines that exert distinct effects on macrophages. Our overexpression studies indicated that SOCS-3 can also inhibit IL-4 signaling in HeLa cells. Therefore, SOCS-3 may contribute to the ability of IFN-g to antagonize IL-4 signaling in a variety of cell types. 8, 20 We found that the induction of SOCS-1 gene expression by IFN-b or IFN-g in macrophages is STAT1-dependent. In contrast, induction of SOCS-3 expression by either IFN-b or IFN-g is STAT1-independent. In fact, IFN-gmediated SOCS-3 expression was greater in STAT1
þ / þ macrophages. Thus, our findings suggest the possibility that SOCS-1 may negatively regulate SOCS-3 gene expression in primary macrophages. Several laboratories have delineated a subset of IFN-inducible genes, including SOCS-3, whose expression does not require STAT1 activation. 21, 22 Furthermore, it has recently been shown that IFN-g induces SOCS-3 expression via its ability to activate STAT3. 23 Sustained IL-4 signaling may be detrimental to the host by facilitating overexpression of IL-4-responsive genes. Defects in STAT6 regulation have been implicated in the pathogenesis of certain diseases, particularly atopic diseases such as asthma. 24, 25 Therefore, controlling STAT6 activity appears to be critical for preventing chronic inflammatory responses. Our findings indicate that IL-4 signaling in macrophages is autoregulated, at least in part, by de novo expression of SOCS-1. In view of the potential importance of the alternative macrophage activation pathway, understanding the regulation of SOCS-1 may provide important new avenues for controlling macrophage activation. 
Materials and methods
Cells
Normal human peripheral blood monocytes were isolated by counter current elutriation in a Beckman JE-6B centrifugal elutriator as described previously. 26 The elutriated monocyte fraction consisted of 495% monocytes as determined by histologic staining and fluorescence-activated cell sorter (FACS) analysis with the anti-CD14 mAb Leu M3 (Becton Dickinson, San Jose, CA, USA). Monocytes were cultured routinely at 4 Â 10 6 cells per ml in complete medium in round-bottomed, polypropylene, tissue culture tubes.
Murine bone marrow-derived macrophages were generated as described previously 27 from bone marrow aspirates extracted from the femurs of wild-type C57BL/ 6 Â 129 mice (Taconic Farms, Germantown, NY, USA), or from specific gene knockout mice, including STAT1-deficient mice, 11, 12 STAT6-deficient mice 5, 6 (Taconic Farms, Germantown, NY), IFN-g-deficient mice and IFNg/SOCS-1-deficient mice. 14, 15 The cells were cultured at 1 Â 10 6 cells/ml in complete RPMI-1640 medium containing recombinant human M-CSF (100 ng/ml) for 5-7 days at 371C.
A panel of stably transfected HeLa cell lines was used to evaluate the effects of SOCS gene expression on the ability of IL-4 to activate STAT6. These cell lines were kindly provided by Dr Ke Shuai (UCLA, Los Angeles, CA, USA). The generation and characterization of these cell lines has been described previously. 13 SOCS protein expression was confirmed by Western blotting with an anti-Flag epitope antibody.
Northern blots
Total RNA was isolated from cultured monocytes or macrophages using RNAzol B (Tel-Test Inc., Friendswood, TX, USA) by the acid/guanidinium thiocyanate/ phenol/chloroform extraction method as described previously. 28 Equivalent amounts of RNA (10 mg per lane) were size-fractionated by electrophoresis in 1% agarose gels containing 0.66 M formaldehyde. The RNA then was transferred onto Nytran membranes and crosslinked by exposure to UV light. The membranes then were hybridized and washed according to standard procedures. The cDNA probes for the SOCS genes were provided by Dr Doug Hilton (Walter & Eliza Hall Research Institute, Melbourne, Australia), and have been described previously. 29 The cDNA probe for arginase-I was provided by Dr Peter Murray (St Jude Children's Research Hospital, Memphis, TN, USA), and was described previously. 30 Gel-purified insert DNA was radiolabeled by the random-primer method of Feinberg and Vogelstein. 31 Ribonuclease protection assays RPAs were performed using the RiboQuant Multi-probe RNase Protection Assay System (BD Biosciences, San Diego, CA, USA) with the SOCS probe template set (Cat. #559927). The probes were transcribed in the presence of [a-33 ]UTP (Cat. #58103; ICN Biomedicals, Irvine, CA, USA). Protected RNA fragments were separated by electrophoresis through 6% polyacrylamide gel electrophoresis (PAGE)-7 M urea sequencing gels (CastAway Precast Sequencing System, Stratagene, La Jolla, CA, USA), and visualized by autoradiography.
Electrophoretic mobility-shift assays Nuclear protein extracts were prepared from cytokinetreated cells by using a modification 32 of the original method described by Dignam et al. 33 A double-stranded oligonucleotide (IL-1ra SBE1) based on a DNA sequence present in the promoter of the human IL-1ra gene was used as a probe in the gel-shift assays. 34 This oligonucleotide contains an N4-type GAS element that can bind STAT6 but not STAT1. Binding reactions were performed as described previously. 32 A portion of each binding reaction mixture (8 ml per sample) was electrophoresed on nondenaturing, 6% polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) by using 0.25 Â Tris-borateethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid buffer (22 mM Tris-HCl, pH 8.0/22 mM borate/0.5 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid). The gels then were dried and visualized by autoradiography.
Western blots
The levels of tyrosine-phosphorylated STAT6 were measured by Western blotting as previously described. 8 After cytokine treatment, the cells were washed three times with Dulbecco's phosphate-buffered saline, and whole-cell lysates were prepared. Total STAT6 protein was immunoprecipitated using rabbit anti-STAT6 antibodies (sc-621; Santa Cruz Biotechnology Inc.). Immunoprecipitated proteins were resolved by electrophoresis on 8% sodium dodecyl sulfate (SDS)-PAGE gels (Invitrogen), and then transferred to polyvinylidene difluoride membranes. The levels of tyrosine-phosphorylated STAT6 (pY-STAT6) or total STAT6 were visualized by enhanced chemiluminescence (ECL) using rabbit antiphospho-Tyr 641 -STAT6 (Cat. #9163L; Cell Signaling Technology Inc., Beverly, MA, USA) or rabbit anti-STAT6 antibodies, respectively. In the experiments using the HeLa cell transfectants that overexpress epitopetagged SOCS proteins, expression of the SOCS proteins was confirmed by immunoblotting whole-cell protein extracts with a monoclonal anti-FLAG antibody (Cat. #F-3165, Sigma-Aldrich, St Louis, MO, USA).
